Historique de carrière de Colin Scott
Anciens postes connus de Colin Scott
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2006 | 31/12/2008 |
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | 01/10/2004 | 01/12/2005 |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Directeur Technique/Scientifique/R&D | 01/09/2002 | 01/05/2004 |
| Conseiller Juridique Général | 01/09/2002 | 01/05/2004 | |
| EMISPHERE TECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 01/03/2001 | 01/05/2002 |
Formation de Colin Scott
| University of Glasgow | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| General Counsel | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVABAY PHARMACEUTICALS, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
- Bourse
- Insiders
- Colin Scott
- Expérience
